Cargando…
Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media
Cold Atmospheric Plasma (CAP) and Plasma Activated Media (PAM) are effective against bacteria, fungi, cancer cells, and viruses because they can deliver Reactive Oxygen and Nitrogen Species (RONS) on a living tissue with negligible damage on health cells. The antiviral activity of CAP against SARS-C...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742116/ https://www.ncbi.nlm.nih.gov/pubmed/34997166 http://dx.doi.org/10.1038/s41598-021-04360-y |
_version_ | 1784629646195687424 |
---|---|
author | Cortázar, Osvaldo Daniel Megía-Macías, Ana Moreno, Sandra Brun, Alejandro Gómez-Casado, Eduardo |
author_facet | Cortázar, Osvaldo Daniel Megía-Macías, Ana Moreno, Sandra Brun, Alejandro Gómez-Casado, Eduardo |
author_sort | Cortázar, Osvaldo Daniel |
collection | PubMed |
description | Cold Atmospheric Plasma (CAP) and Plasma Activated Media (PAM) are effective against bacteria, fungi, cancer cells, and viruses because they can deliver Reactive Oxygen and Nitrogen Species (RONS) on a living tissue with negligible damage on health cells. The antiviral activity of CAP against SARS-CoV-2 is being investigated, however, the same but of PAM has not been explored despite its potential. In the present study, the capability of Plasma Activated Media (PAM) to inactivate SARS-CoV-2 and PR8 H1N1 influenza virus with negligible damage on healthy cells is demonstrated. PAM acted by both virus detaching and diminished replication. Furthermore, the treatment of A549 lung cells at different times with buffered PAM did not induce interleukin 8 expression, showing that PAM did not induce inflammation. These results open a new research field by using PAM to the development novel treatments for COVID-19, influenza, and other respiratory diseases. |
format | Online Article Text |
id | pubmed-8742116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87421162022-01-11 Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media Cortázar, Osvaldo Daniel Megía-Macías, Ana Moreno, Sandra Brun, Alejandro Gómez-Casado, Eduardo Sci Rep Article Cold Atmospheric Plasma (CAP) and Plasma Activated Media (PAM) are effective against bacteria, fungi, cancer cells, and viruses because they can deliver Reactive Oxygen and Nitrogen Species (RONS) on a living tissue with negligible damage on health cells. The antiviral activity of CAP against SARS-CoV-2 is being investigated, however, the same but of PAM has not been explored despite its potential. In the present study, the capability of Plasma Activated Media (PAM) to inactivate SARS-CoV-2 and PR8 H1N1 influenza virus with negligible damage on healthy cells is demonstrated. PAM acted by both virus detaching and diminished replication. Furthermore, the treatment of A549 lung cells at different times with buffered PAM did not induce interleukin 8 expression, showing that PAM did not induce inflammation. These results open a new research field by using PAM to the development novel treatments for COVID-19, influenza, and other respiratory diseases. Nature Publishing Group UK 2022-01-07 /pmc/articles/PMC8742116/ /pubmed/34997166 http://dx.doi.org/10.1038/s41598-021-04360-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Cortázar, Osvaldo Daniel Megía-Macías, Ana Moreno, Sandra Brun, Alejandro Gómez-Casado, Eduardo Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media |
title | Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media |
title_full | Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media |
title_fullStr | Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media |
title_full_unstemmed | Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media |
title_short | Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media |
title_sort | vulnerability of sars-cov-2 and pr8 h1n1 virus to cold atmospheric plasma activated media |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742116/ https://www.ncbi.nlm.nih.gov/pubmed/34997166 http://dx.doi.org/10.1038/s41598-021-04360-y |
work_keys_str_mv | AT cortazarosvaldodaniel vulnerabilityofsarscov2andpr8h1n1virustocoldatmosphericplasmaactivatedmedia AT megiamaciasana vulnerabilityofsarscov2andpr8h1n1virustocoldatmosphericplasmaactivatedmedia AT morenosandra vulnerabilityofsarscov2andpr8h1n1virustocoldatmosphericplasmaactivatedmedia AT brunalejandro vulnerabilityofsarscov2andpr8h1n1virustocoldatmosphericplasmaactivatedmedia AT gomezcasadoeduardo vulnerabilityofsarscov2andpr8h1n1virustocoldatmosphericplasmaactivatedmedia |